Ligand Pharmaceuticals Cash Flow Statement (2010-2026) | LGND

Cash Flow Statement Jun2010 Sep2010 Dec2010 Mar2011 Jun2011 Sep2011 Dec2011 Mar2012 Jun2012 Sep2012 Dec2012 Mar2013 Jun2013 Sep2013 Dec2013 Mar2014 Jun2014 Sep2014 Dec2014 Mar2015 Jun2015 Sep2015 Dec2015 Mar2016 Jun2016 Sep2016 Dec2016 Mar2017 Jun2017 Sep2017 Dec2017 Mar2018 Jun2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Operating Activities
Net Income (Quarter)
-6.62M-2.22M-2.46M-13.49M-9.24M-2.95M-1.67M-31.09M-42.45M4.85M117.27M44.78M-13.35M48.51M
Depreciation and Depletion (Quarter)
0.58M0.60M0.74M0.39M0.51M0.26M0.17M0.05M0.12M0.12M
Share-based Compensation (Quarter)
9.75M-22.36M5.86M0.06M25.22M-31.14M4.16M-4.16M11.06M15.17M39.32M0.83M10.00M14.75M-22.98M21.73M13.65M
Deferred Taxes (Quarter)
-1.54M0.39M16.18M-3.25M12.64M-46.29M-8.75M10.00M-8.01M-4.93M-19.55M20.67M1.99M12.69M8.84M0.33M-21.28M-10.57M13.53M-12.98M
Cash from Discontinued Operations (Quarter)
Asset Writedowns and Impairment (Quarter)
0.92M4.08M6.20M
Cash from Operations (Quarter)
20.02M27.64M52.01M11.88M20.49M53.47M33.95M-0.08M7.65M8.06M18.73M13.31M36.53M28.47M-25.45M15.80M13.09M45.91M48.69M24.02M
Depreciation, Depletion & Amortization
Amortizatization of Intangibles (Quarter)
-0.04M0.03M-0.05M0.01M-0.03M0.06M0.28M0.38M0.28M0.38M0.16M0.43M0.14M0.61M0.84M0.77M1.34M2.02M1.50M1.20M
Amortization of Deferred Charges (Quarter)
3.79M3.83M0.33M0.20M0.10M0.10M0.10M0.10M0.08M0.08M0.10M0.13M0.17M0.14M0.12M0.40M0.56M0.80M0.70M
Depreciation & Amortization (CF) (Quarter)
12.72M13.17M13.65M13.27M13.48M11.13M9.50M9.49M8.61M8.92M8.77M8.85M8.99M8.63M8.77M8.52M8.27M8.21M8.22M8.21M
Change in Working Capital
Change in Receivables (Quarter)
6.18M19.78M-43.64M20.43M2.66M-34.77M-1.10M-1.38M7.91M-2.83M-3.46M9.05M-4.79M5.67M0.58M2.77M16.31M2.09M-6.41M13.85M
Change in Inventory (Quarter)
0.78M-2.68M-0.04M-9.70M-0.96M-1.36M-2.04M13.00M0.61M-0.71M-2.63M-2.49M-1.93M-2.57M0.50M0.88M-3.59M-2.77M4.14M-3.00M
Change in Accured Expenses (Quarter)
0.70M6.45M-2.71M-1.65M3.95M-2.94M-0.43M-4.53M-2.50M2.76M-1.38M1.77M2.23M11.29M-2.15M-0.41M1.09M7.34M2.71M3.25M
Change in Taxes (Quarter)
-1.69M11.99M-2.98M6.10M4.61M11.39M-10.18M
Other Working Capital Changes (Quarter)
-6.09M-2.45M0.20M2.27M-0.10M
Investing Activities
Capital Expenditures (Quarter)
-4.24M1.01M4.88M-1.07M-0.17M14.30M2.41M-1.88M2.57M-3.10M0.10M0.41M0.60M0.71M0.21M-0.20M-0.01M0.21M0.23M0.03M
Sales of Property, Plant and Equipment (Quarter)
Change in Intangibles (Quarter)
Acquisitions (Quarter)
-92.00M
Divestments (Quarter)
0.43M0.61M
Change in Acquisitions & Divestments (Quarter)
117.86M-85.36M24.83M152.72M-152.72M184.73M8.46M12.20M75.65M-50.92M60.92M37.99M-71.16M5.38M38.41M44.81M-44.62M120.98M119.35M123.21M
Cash from Investing Activities (Quarter)
-18.22M-35.71M113.88M37.85M19.18M-7.28M10.55M7.56M-19.50M-10.28M-3.77M-54.76M-46.51M-38.62M4.89M-10.67M-353.44M-18.10M-94.35M321.12M
Financing Activities
Other financing activities (Quarter)
1.90M4.28M-0.12M0.09M-0.01M3.27M3.39M9.14M3.39M-15.92M15.30M9.55M21.39M-46.25M4.22M8.24M-19.89M7.65M114.10M
Cash from Financing Activities (Quarter)
-0.39M4.16M-170.42M-59.44M-40.83M-5.30M-0.78M-67.76M3.27M5.32M12.18M9.49M55.08M20.39M-4.75M14.99M409.64M8.33M-14.13M546.43M
Change in Capital Stock
Net Equity Issued and Repurchased (Quarter)
3.11M
Additional items
Exchange Rate Effect (Quarter)
-4.82M5.19M-1.55M1.06M2.29M-0.40M-0.59M-0.04M0.04M
Change in Cash (Quarter)
1.42M-3.91M-4.53M-9.71M-1.16M40.89M43.72M-60.28M-8.59M3.10M27.14M-27.14M40.66M8.69M-24.32M19.68M71.71M35.55M-59.83M891.61M
Free Cash Flow (Quarter)
24.26M26.63M47.14M12.95M20.66M39.17M31.53M1.80M5.07M11.17M18.63M12.91M35.93M27.76M-25.66M16.00M13.10M45.70M48.46M23.99M
Net Cash Flow (Quarter)
1.42M-3.91M-4.53M-9.71M-1.16M40.89M43.72M-60.28M-8.59M3.10M27.14M-31.95M45.10M10.24M-25.30M20.13M69.29M36.14M-59.79M891.57M